Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Equity

The The Equity of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 23, 2026 is 5.69 B CNY. In the previous year, The Equity was 5.35 B CNY — a change of 6.32% (higher).

Equity

5.69 BCNY

YoY

6.32%

Last updated:

In 2025, Harbin Pharmaceutical Group Co's equity was 5.69 B CNY, a 6.32% increase from the 5.35 B CNY equity in the previous year.

The Harbin Pharmaceutical Group Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
5.87 B CNY
Jan 1, 2019
5.46 B CNY
Jan 1, 2020
3.48 B CNY
Jan 1, 2021
3.85 B CNY
Jan 1, 2022
4.33 B CNY
Jan 1, 2023
4.72 B CNY
Jan 1, 2024
5.35 B CNY
Jan 1, 2025
5.69 B CNY
The Harbin Pharmaceutical Group Co Equity history
YEAREquityYoY
5.69 BCNY+6.32%
5.35 BCNY+13.24%
4.72 BCNY+9.07%
4.33 BCNY+12.58%
3.85 BCNY+10.56%
3.48 BCNY-36.23%
5.46 BCNY-6.97%
5.87 BCNY-16.82%
7.05 BCNY-10.20%
7.85 BCNY+11.34%
7.05 BCNY-14.39%
8.24 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Harbin Pharmaceutical Group Co's Equity

Harbin Pharmaceutical Group Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Harbin Pharmaceutical Group Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Harbin Pharmaceutical Group Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Harbin Pharmaceutical Group Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Harbin Pharmaceutical Group Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

The Equity of Harbin Pharmaceutical Group Co is 5.69 B CNY in 2025.

The Equity of Harbin Pharmaceutical Group Co changed from 5.35 B CNY to 5.69 B CNY, representing a 6.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Harbin Pharmaceutical Group Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Harbin Pharmaceutical Group Co